Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
170 participants
OBSERVATIONAL
2011-02-28
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to cat dander in the EEC among subjects who completed all dosing visits in study CP005 approximately one year after the start of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cat-PAD Exposure Chamber Study
NCT01033344
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
NCT00867906
An Optional Two Year Follow Up Study to Study CP005A
NCT01604018
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
NCT00729508
Phase III Cat-PAD Follow-on Study
NCT02040844
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Subjects previously randomised to receive placebo in study CP005
Placebo
No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Cat-PAD Group 1
Subjects previously randomised to receive Cat-PAD dose 1 in study CP005
Cat-PAD Dose 1
No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Cat-PAD Group 2
Subjects previously randomised to receive Cat-PAD dose 2 in study CP005
Cat-PAD Dose 2
No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Cat-PAD Dose 1
No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Cat-PAD Dose 2
No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of anaphylaxis to cat allergen
* FEV1 of less than 70% of predicted
* Subjects who cannot tolerate baseline challenge in the EEC
* Treatment with beta-blockers,Alpha-adrenoceptor blockers, Tranquillizers or psychoactive drugs
* A history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cetero Research, San Antonio
NETWORK
Adiga Life Sciences, Inc.
INDUSTRY
Circassia Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Circassia Ltd
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Couroux, MD
Role: PRINCIPAL_INVESTIGATOR
Cetero Research, San Antonio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cetero Research
Mississauga, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP005A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.